Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1326 ARTÍCULOS , VIENDO DEL 406 AL 420

Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation

Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S.

J Alzheimers Dis. 2010;21(2):361-71. doi: 10.3233/JAD-2010-100150.

Physical activity and mild cognitive impairment and Alzheimer's disease

Lautenschlager NT, Cox K, Kurz AF.

Curr Neurol Neurosci Rep. 2010 Sep;10(5):352-8. doi: 10.1007/s11910-010-0121-7.

[Colivelin--drug therapy for patients with Alzheimer's disease]

Matsuoka M.

Nihon Yakurigaku Zasshi. 2010 Jun;135(6):263.

Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities

Rosenblatt A, Gao J, Mackell J, Richardson S.

Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):483-9. doi: 10.1177/1533317510372923. Epub 2010 Jun 17.

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state

Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, Seripa D, Vendemiale G, Pilotto A, Solfrizzi V.

CNS Neurosci Ther. 2010 Oct;16(5):272-84. doi: 10.1111/j.1755-5949.2010.00164.x. Epub 2010 Jun 16.

Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?

Martorana A, Esposito Z, Koch G.

CNS Neurosci Ther. 2010 Aug;16(4):235-45. doi: 10.1111/j.1755-5949.2010.00175.x. Epub 2010 Apr 16.

Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease

Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN.

Vaccine. 2010 Jul 19;28(32):5280-7. doi: 10.1016/j.vaccine.2010.05.054. Epub 2010 Jun 4.

Isolated bulbar paralysis in a patient with medullar tau pathology: a case report

Pretnar-Oblak J, Zaletel M, Hajnsek TM, Meglic B, Hocevar-Boltezar I, Popovic M.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):847-9. doi: 10.1136/jnnp.2008.169029. Epub 2010 Jun 20.

[Implications of Alzheimer's disease for the caregiver's quality of life: a comparative study]

Inouye K, Pedrazzani ES, Pavarini SC.

Cad Saude Publica. 2010 May;26(5):891-9. doi: 10.1590/s0102-311x2010000500011.

Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review

Uro-Coste E, Russano de Paiva G, Guilbeau-Frugier C, Sastre N, Ousset PJ, da Silva NA, Lavialle-Guillotreau V, Vellas B, Delisle MB.

Clin Neuropathol. 2010 Jul-Aug;29(4):209-16. doi: 10.5414/npp29209.

Automated MRI measures predict progression to Alzheimer's disease

Desikan RS, Cabral HJ, Settecase F, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Salat DH, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1364-74. doi: 10.1016/j.neurobiolaging.2010.04.023. Epub 2010 Jun 8.

Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials

McArthur RA, Gray J, Schreiber R.

Curr Opin Investig Drugs. 2010 Jul;11(7):740-60.

Cholesterol-related genes in Alzheimer's disease

Wollmer MA.

Biochim Biophys Acta. 2010 Aug;1801(8):762-73. doi: 10.1016/j.bbalip.2010.05.009. Epub 2010 May 24.

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

Palop JJ, Mucke L.

Nat Neurosci. 2010 Jul;13(7):812-8. doi: 10.1038/nn.2583.

Pathological implications of cell cycle re-entry in Alzheimer disease

Bonda DJ, Lee HP, Kudo W, Zhu X, Smith MA, Lee HG.

Expert Rev Mol Med. 2010 Jun 29;12:e19. doi: 10.1017/S146239941000150X.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias